Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $201.6 million.

  • Arrowhead Pharmaceuticals' Cash & Equivalents rose 27418.21% to $201.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $201.6 million, marking a year-over-year increase of 27418.21%. This contributed to the annual value of $226.5 million for FY2025, which is 12062.42% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Cash & Equivalents stood at $201.6 million, which was up 27418.21% from $226.5 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Cash & Equivalents high stood at $372.4 million for Q1 2021, and its period low was $39.3 million during Q4 2021.
  • For the 5-year period, Arrowhead Pharmaceuticals' Cash & Equivalents averaged around $148.2 million, with its median value being $128.8 million (2024).
  • Data for Arrowhead Pharmaceuticals' Cash & Equivalents shows a peak YoY increase of 41512.66% (in 2022) and a maximum YoY decrease of 7679.7% (in 2022) over the last 5 years.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Cash & Equivalents (Quarter) stood at $39.3 million in 2021, then skyrocketed by 415.13% to $202.2 million in 2022, then crashed by 71.22% to $58.2 million in 2023, then decreased by 7.43% to $53.9 million in 2024, then soared by 274.18% to $201.6 million in 2025.
  • Its Cash & Equivalents was $201.6 million in Q4 2025, compared to $226.5 million in Q3 2025 and $129.8 million in Q2 2025.